

Arthritis Models




Tools to Study the Role of Bacterial Agents in Rheumatoid Arthritis

Chondrex, Inc. provides three protocols to develop mouse arthritis models that are ideal for studying the pathological effects of bacterial agents in the development of rheumatoid arthritis (RA). For more information, please contact Chondrex, Inc. at support@chondrex.com.


1. Collagen Antibody-Induced Arthritis (CAIA)

CAIA is the fastest, most consistent arthritis model to study the pathogenic roles of bacterial agents involved in RA and other autoimmune diseases. Arthritis is induced in mice within 24 - 48 hours by a single injection of a sub-arthritogenic dose of Arthrogen-CIA® monoclonal antibody cocktail followed by (a) IP injection or (b) oral administration of bacterial toxins such as lipopolysaccharide (LPS). Interestingly, oral administration of LPS triggers arthritis in old mice (8 months old) but not in young mice (8 weeks old), indicating significant age-associated changes in the mucosal barrier function as seen in Figure (c).


a) Arthritis Triggered by IP Injection of LPS (1)



b) Arthritis Triggered by Oral Administration of LPS (2)



c) Susceptibility to Intestinal LPS Associated with Aging



Procedure

- Day 0: IV injection of Arthrogen-CIA® monoclonal antibody cocktail.
- Day 5: IP injection of LPS (50 µg) or test samples.
- NOTE: LPS can be injected up to 5 days after mAb injection. Serum cytokine level is a marker for the pathogenic effect of test samples.

Procedure

- Day 0: IV injection of Arthrogen-CIA® monoclonal antibody cocktail.
- Day 1: Oral administration of LPS (1 3 mg/mouse) with and without an LPS-adsorbent.
- NOTE: Severity of arthritis (day 7) correlates with serum IL-6 levels 6 hours after LPS oral administration.

Comparing Age

Young mice (8 weeks old) are resistant to orally administered LPS, whereas old mice (8 months old) are susceptible to LPS absorption, consequently resulting in an increase in serum IL-6 levels.

NOTE: Anesthetization with isoflurane increases serum IL-6, indicating a possible effect on mucosal barrier function.

Chondrex, Inc.

24




Arthritis Models



2. Collagen-Induced Arthritis (CIA) (3)

CIA is a flexible model that is ideal to study the long-term effects of a plethora of intestinal bacteria and their toxins in RA development. Sub-arthritogenic immunization of type II collagen (CII) is followed by oral administration of LPS, leading to arthritis in low responding mice.




Procedure

Day 0: Immunization with CII/CFA (*Mycobacterium tuberculosis*: 1 mg/ml: Suboptimal condition).

- Day 42: Oral administration of LPS (1 3 mg) or other bacterial agents into low responding mice (red).
- Day 43: Observe the exacerbation and perpetuation of arthritis.

3. Oral Collagen-Induced Arthritis (OCIA) and Others (4)

This arthritis model is useful in studying the long-term effects of bacterial agents, such as intestinal microbes, in conjunction with the host's immune function. Long term oral administration of a mimic antigen (heterologous type II collagen: CII) and a bacterial toxin (LPS) induces mild, but chronic arthritis.



References

- 1. <u>K. Terato, D. Harper, M. Griffiths, D. Hasty, X. Ye, et al., Collagen-induced arthritis in mice: synergistic effect of E. coli lipopolysaccharide bypasses epitope specificity in the induction of arthritis with monoclonal antibodies to type II collagen. *Autoimmunity* 22, 137-47 (1995).</u>
- K. Terato, C. Do, H. Shionoya, Slipping through the Cracks: Linking Low Immune Function and Intestinal Bacterial Imbalance to the Etiology of Rheumatoid Arthritis. Autoimmune Dis 2015, 636207 (2015).
- S. Yoshino, E. Sasatomi, Y. Mori, M. Sagai, Oral administration of lipopolysaccharide exacerbates collagen-induced arthritis in mice. J Immunol 163, 3417-22 (1999).
- 4. <u>K. Terato, X. Ye, H. Miyahara, M. Cremer, M. Griffiths, Induction by chronic autoimmune arthritis in DBA/1 mice by oral administration of type II collagen and Escherichia coli lipopolysaccharide. *Br J Rheumatol* **35**, 828-38 (1996).</u>